AstraZeneca vaccine again in turmoil
The pharmaceutical risks of the AstraZeneca vaccine are still being analyzed ... REUTERS - SERGIO PEREZ
Text by: RFI Follow
2 min
According to an official from the European Medicines Agency, there is indeed a link between the AstraZeneca vaccine and the blood clotting problems observed after its administration.
A serious statement that has not yet been confirmed by the EMA.
Publicity
Read more
The pharmaceutical risks of the AstraZeneca vaccine are still being analyzed.
This is repeated in a press release by the European Medicines Agency (EMA).
She says she has not yet reached a conclusion and thus qualifies the words of Marco Cavaleri, head of the vaccine strategy at the EMA.
Interviewed Tuesday morning in the Italian press, this member of the EMA had affirmed the existence of a clear link between cases of thrombosis and the vaccine.
Less than a month ago, several countries had suspended the administration of the vaccine for a time after the observation of rare side effects in 62 people in Europe.
AstraZeneca vaccination has since resumed.
The agency does not rule out the possible formation of blood clots in people under the age of 60, but with 1 in 100,000 cases, they estimate for now that the benefits outweigh the risks.
Examinations are therefore continuing to determine the causes of the adverse effects in certain patients.
These results should be communicated on Wednesday or Thursday, according to the European regulator.
►
To read also: In the spotlight: the AstraZeneca vaccine between challenge and mistrust
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Coronavirus
Vaccines